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The Parkinson’s gene PINK1 regulates cell cycle progression
and promotes cancer-associated phenotypes
CH O’Flanagan1, VA Morais2,3, W Wurst4,5,6, B De Strooper2,3,7 and C O’Neill1
PINK1 (phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-induced kinase 1), a Parkinson’s disease-associated
gene, was identiﬁed originally because of its induction by the tumor-suppressor PTEN. PINK1 promotes cell survival and potentially
metastatic functions and protects against cell stressors including chemotherapeutic agents. However, the mechanisms underlying
PINK1 function in cancer cell biology are unclear. Here, using several model systems, we show that PINK1 deletion signiﬁcantly
reduced cancer-associated phenotypes including cell proliferation, colony formation and invasiveness, which were restored by
human PINK1 overexpression. Results show that PINK1 deletion causes major defects in cell cycle progression in immortalized
mouse embryonic ﬁbroblasts (MEFs) from PINK1 / mice, and in BE(2)-M17 cells stably transduced with short hairpin RNA against
PINK1. Detailed cell cycle analyses of MEF cell lines from several PINK1 / mice demonstrate an increased proportion of cells in
G2/M and decreased number of cells in G1 following release from nocodazole block. This was concomitant with increased double
and multi-nucleated cells, a reduced ability to undergo cytokinesis and to re-enter G1, and signiﬁcant alterations in cell cycle
markers, including failure to increase cyclin D1, all indicative of mitotic arrest. PINK1 / cells also demonstrated ineffective cell
cycle exit following serum deprivation. Cell cycle defects associated with PINK1 deﬁciency occur at points critical for cell division,
growth and stress resistance in cancer cells were rescued by ectopic expression of human PINK1 and demonstrated PINK1 kinase
dependence. The importance of PINK1 for cell cycle control is further supported by results showing that cell cycle deﬁcits induced
by PINK1 deletion were linked mechanistically to aberrant mitochondrial ﬁssion and its regulation by dynamin-related protein-1
(Drp1), known to be critical for progression of mitosis. Our data indicate that PINK1 has tumor-promoting properties and
demonstrates a new function for PINK1 as a regulator of the cell cycle.
Oncogene advance online publication, 31 March 2014; doi:10.1038/onc.2014.81
INTRODUCTION
PINK1 (phosphatase and tensin homolog deleted on chromosome 10
(PTEN)-induced kinase 1) was ﬁrst identiﬁed in HeLa cells as a gene
upregulated by overexpression of the central tumor suppressor,
PTEN.1 Subsequently, loss of function mutations in PINK1 were
discovered to cause autosomal recessive Parkinson’s disease,2 and
a wealth of research on PINK1 function in neuronal and other cell
systems emerged.3–8 The PINK1 gene encodes a 581-amino-acid
protein with a highly conserved serine/threonine kinase domain,
a C-terminal auto-regulatory sequence and a mitochondrial-
targeting signal.9,10 PINK1 is ubiquitously expressed,11 and is a
major regulator of mitochondrial quality control, including
bioenergetics and the triad of ﬁssion, fusion and mitophagy.12–14
PINK1 also demonstrates signiﬁcant cytoprotective and anti-
apoptotic functions,5,6,15,16 including via the phosphatidylinositol
3 kinase/Akt/mammalian target of rapamycin axis17,18
proteasomal19–21 and autophagic pathways.22,23
Many of the functions of PINK1 draw increasing attention to the
importance of this kinase in regulation of cell survival systems
outside those protecting from neurodegeneration in Parkinson-
ism. This is especially pertinent when considering cell survival in
cancer, where a number of studies have indicated a potential role
for PINK1 in tumorigenesis.17,24–26 However, the mechanisms
underlying PINK1 function in cancer biology are not clear and
have been the subject of only a few investigations, with
conﬂicting evidence as to whether PINK1 has tumor-promoting
or -suppressive activity. When considering tumor promotion,
PINK1 is necessary for optimal activation of insulin-like growth
factor-1 receptor–phosphatidylinositol 3 kinase/Akt signaling, a
well-described oncogenic pathway.18 Moreover, PINK1-mediated
activation of Akt via mammalian target of rapamycin complex
2 increases migration, a key feature of invasive cancer cells.17
High-throughput RNA interference screens have identiﬁed PINK1
deletion as a primary sensitizer of chemoresistant cancer cells to
cell death following treatment with paclitaxel26 and as a target
for treatment of malignancies with DNA mismatch repair
deﬁciencies.25 In the context of tumor suppression, PINK1 is
induced by PTEN1 and FOXO3a27 tumor suppressors, and
associates with Beclin-1, another tumor suppressor.22 Parkin,
an autosomal recessive Parkinson’s disease-causing gene, can
function downstream of PINK1 (reviewed in Jin and Youle28
and Wilhelmus and Nijland29) and is also a tumor suppressor.30–32
The PINK1 gene is located on chromosome 1p361, a region
postulated to contain tumor-suppressive activity.33 Such opposing
context-dependent pro- and antitumorigenic properties are
emerging to be common for many genes with tumorigenic
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potential,34,35 and it has been postulated that PINK1 may have a
dual role, being either anti-apoptotic or anti-growth depending on
cellular context.24
Many of the mitochondrial functions ascribed to PINK1 are
centrally linked to regulation of cell death and survival in
cancer cells. Mitochondrial ﬁssion is strongly associated with
apoptosis36,37 and mitochondrial DNA mutations, altered meta-
bolic pathways, increased mitochondrial reactive oxygen species,
and deregulated mitochondrial dynamics contribute to the
development of malignant cells.38–41 It is well documented that
regulation of the ﬁssion/fusion axis via the mitochondrial ﬁssion
GTPase dynamin-related protein-1 (Drp1) is a major function of
PINK1 in Drosophila.42–44 In dividing mammalian cells, PINK1
deletion causes excessive ﬁssion, and deletion of Drp1 can rescue
the PINK1-null phenotype.13,45 Importantly, the mitochondrial
ﬁssion/fusion and bioenergetic balance is critical for cell cycle
progression, cell division and growth, with ﬁssion being essential
for equal distribution of mitochondria during mitosis,46–48
whereas fused mitochondrial networks are important for
progression from G1 to S phase49 and stress resistance during
starvation.50,51
Much evidence thus supports a function for PINK1 in cancer cell
biology, although the underlying mechanism(s) are unclear.
Therefore, this study aimed to investigate PINK1 function in
cancer cell phenotypes. Our results show, for the ﬁrst time, that
PINK1 deletion causes cell cycle defects associated with aberrant
regulation of mitochondrial ﬁssion, and highlight PINK1 as a
regulator of the cell cycle and as a candidate oncogene.
RESULTS
PINK1 deletion suppresses several cancer-associated phenotypes
Initial experiments aimed to determine the impact of PINK1
deletion on tumor-associated phenotypes including cell prolifera-
tion, colony formation, migration and invasiveness (Figure 1). Cells
with PINK1 deletion including several immortalized mouse
embryonic ﬁbroblast (MEF) lines derived from n= 3 PINK1/
mice, HeLa cells with stable knockdown of PINK1 and MCF-7 cells
with transient knockdown of PINK1, all demonstrated signiﬁcantly
reduced proliferation rates compared with controls (Figure 1a).
The slower growth rate of PINK1 / compared with PINK1+/+
MEFs, was rescued by overexpression of human wild-type PINK1
(hPINK1res), but not by the triple kinase dead
52 PINK1 mutant
(hPINK1K219A/D362A/D384A) (Figure 1a). Colony formation assays
revealed a signiﬁcant decrease in clonogenic potential in
PINK1/ compared with PINK1+/+ MEFs, which was restored in
hPINK1res cells, but not by hPINK1K219A/D362A/D384A (Figure 1b).
Reduced colony formation was also observed in HeLa cells with
stable PINK1 knockdown (Figure 1c), although not in MCF-7 cells
with transient PINK1 deletion via small interfering RNA (siRNA)
(data not shown), most likely due to the transient nature of siRNA
deletion. Though deletion of PINK1 did not alter cell migration in
wound-healing assays of ﬁbroblasts, overexpression of human
PINK1 caused a signiﬁcant increase in cell migration (Figure 1d), as
was found also using transwell migration assays (data not shown).
In addition, PINK1 / cells were found to be less invasive than
their PINK1+/+ counterparts (Figure 1e), which was rescued in
hPINK1res MEFs. Taken together, these results indicate that PINK1 is
required for key cell phenotypes associated with cancer progression.
PINK1 deﬁciency alters cell cycle proﬁle and increases the
frequency of multi-nucleated cells
We were next interested to examine the mechanism by which
PINK1 deletion reduced tumorigenic phenotypes. Here, we
focused ﬁrst on analysis of immortalized MEF cell lines derived
from three pairs of PINK1+/+ and PINK1/ mice. Microscopic
examination of these PINK1/ MEFs revealed morphological
differences compared with PINK1+/+ MEFs, whereby PINK1/
cells appeared larger and ﬂatter, a description commonly used
for senescent cells.53 Use of a senescence assay to detect
β-galactosidase activity (Figure 2a) and cell cycle analysis
(Figure 2b) with late passage (p6) non-immortalized MEFs as a
positive control showed only p6 MEFs were senescent, as shown
by reduced cycling cells and increased cells in G0/G1.
However, these results did reveal signiﬁcant differences in the
cell cycle proﬁle of PINK1/ compared with PINK1+/+ cells,
whereby deletion of PINK1 caused a signiﬁcant increase in the
number of cells in G2/M phase, concomitant with a signiﬁcant
decrease in the percentage of cells in G0/G1 phases (Figure 2b).
These changes were rescued by overexpression of human PINK1,
although not rescued by the PINK1K219A/D362A/D384A mutant
(Figure 2b). This observation was supported by morphological
analysis of each of the three independently derived PINK1/
MEF lines, which consistently revealed a highly signiﬁcant increase
in the frequency of double and multi-nucleated cells compared
with PINK1+/+ MEFs (Figure 2c). This phenotype was rescued in
hPINK1res MEFs and signiﬁcantly less effectively in hPINK1K219A/
D362A/D384A MEFs. (Figure 2c). Results further showed that, similar
to MEFs lacking PINK1, BE(2)-M17, a dopaminergic neuroblastoma
cell line, stably transduced with short hairpin RNA (shRNA)
sequences directed against PINK113 demonstrated a signiﬁcant
increase in the number of cells in G2/M phase, concomitant with a
signiﬁcant decrease in the percentage of cells in G0/G1 phases,
compared with cells with control shRNA and the parental BE(2)-
M17 line (Supplementary Figure 1).
Taken together, these results indicate that PINK1 deletion alters
cell cycle proﬁle, increasing both the number of cells in G2/M and
multi-nucleated cells, a phenotype that would impact on effective
cell division and growth, which is rescued by overexpression of
PINK1 and involves PINK1 kinase activity.
PINK1 deletion impairs cell division during G2/M
Next, we performed a more stringent analyses of the impact of
PINK1 deletion at G2/M phase following synchronization with the
mitotic spindle inhibitor nocodazole. The percentage of cells in
G2/M did not reduce over time in PINK1 / MEFs following
release from nocodazole block, as seen in PINK1+/+ MEFs
(Figure 3a, Supplementary Figure 2). Thus, PINK1/ cells
remained in G2/M phase up to 2 h post-nocodazole release
(Figure 3a), which was rescued by overexpression of hPINK1. A
high proportion of hPINK1K219A/D362A/D384A MEFs also remained in
G2/M, but by 2 h, this population was reduced, although not to
the same extent as PINK1+/+ or hPINK1res MEFs.
The inability of PINK1-deﬁcient cells to exit G2/M phase was also
observed using double immunoﬂuorescence with 4,6-diamidino-
2-phenylindole and α-tubulin, which showed that the majority of
PINK1/ cells had not divided 2 h post-release from nocodazole
block (Figure 3b). PINK1-deﬁcient cells underwent chromosome
segregation and nuclear envelope reformation, indicating that
this defect occurs at cytokinesis. In contrast at this time point,
PINK1+/+, and hPINK1res cells had divided into two daughter cells
associated only by the tubulin-rich midbody, indicative of the end
stage of cytokinesis. hPINK1K219A/D362A/D384A MEFs showed both
dividing cells and multi-nucleated cells, indicating only partial
rescue of the cell division defect at this time point (Figure 3b).
Together, these data indicate that the inability to progress from
G2/M to G1 induced by PINK1 deﬁciency is rescued by human
PINK1 and involves PINK1 kinase activity. Immunoﬂuorescence
microscopy revealed that human PINK1 localized to distinct poles
at the periphery of the mitotic plane throughout mitosis and
showed increased colocalization with the tubulin cytoskeleton at
cytokinesis (Supplementary Figure 3).
Results further showed signiﬁcant alterations in the proﬁle
of key cell cycle-associated proteins in PINK1/ compared
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with PINK1+/+ ﬁbroblasts up to 24 h post-release from nocodazole
block (Figure 3c), consistent with the altered cell cycle proﬁle.
Phospho-histone H3, which is phosphorylated early in mitosis, is
not phosphorylated at 6 h or even up to 24 h following
nocodazole release in PINK1/ cells, as occurs in PINK1+/+ MEFs,
with partial rescue in hPINK1res cells, indicating that PINK1
/
cells do not undergo subsequent mitosis at the same rate as the
control cells. Total histone H3 levels were not signiﬁcantly
different in PINK1/ , PINK1+/+ or hPINK1res cells. Moreover,
cyclin D1, whose increase in G1 phase is essential for cell cycle
entry, is markedly reduced at all time points in PINK1/
compared with PINK1+/+ cells, with cyclin D1 expression levels
restored toward wild-type levels in hPINK1res cells.
The mitotic kinase (MBP, mitotic-promoting factor) cyclin
B1/Cdk1 is essential for initiation of the mitotic programme with
reduction of cyclin B1 levels being necessary for mitotic exit.46
Cyclin B1 and Cdk1 expression proﬁles are altered in PINK1 /
compared with PINK1+/+ MEFs, with cyclin B1 failing to increase
at later time points and increased Cdk1 expression at all time
points in PINK1/ MEFs (Figure 3c). Unlike cyclin D1 expression
Figure 1. PINK1 deletion reduced cancer-causing phenotypes. (a) Growth rates of immortalized PINK1+/+ (circles), PINK1/ (squares),
hPINK1res (triangles) and hPINK1K219A/D362A/D384A (asterisks) MEFs; HeLa (circles) and shPINK1 HeLa cells (squares); and MCF-7 cells transfected
with negative control (diamonds) or PINK1 siRNA (squares). Cells were seeded at a density of 4 × 104 cells per well and growth was monitored
every 24 h by cell counting. Curves are representative of mean± s.e.m. of immortalized MEF cell lines derived from PINK1+/+ (n= 3) and
PINK1/ (n= 3) mice. (b) Colony formation assays of PINK1+/+, PINK1 / , hPINK1res, hPINK1K219A/D362A/384A MEFs (c) control and shPINK1
HeLa cells. Cells were cultured in soft agarose for 14–21 days and resulting colonies were stained and counted. The graph in (b) and (c) shows
the mean± s.e.m. values for triplicate wells of three independent experiments. For MEFs and Hela cells, the number of colonies is signiﬁcantly
decreased by PINK1 deletion (***Po0.001, Student’s t-test). In MEFs, the colony number is signiﬁcantly restored by hPINK1res rexpression
(***Po0.001, Student’s t-test) but not so by the hPINK1K219A/D362A/384A mutant (ns, nonsigniﬁcant) (d) Scratch wound migration assay of
PINK1+/+, PINK1/ and hPINK1res MEFs. Monolayers were scored and cells were allowed to migrate into the wound for 8 h. Graph shows
quantiﬁcation of the mean± s.e.m. % wound closure of triplicate wells of a representative experiment (*Po0.05, Student’s t-test;
ns, nonsigniﬁcant). (e) Invasion assay of PINK1+/+, PINK1/ and hPINK1res MEFs. Cells were deprived of serum and allowed to migrate into a
matrigel-coated transwell chamber for 24 h toward media containing 10% serum. Invasive cells were stained and photographed on a light
microscope. Graphs represent mean± s.e.m. of triplicate wells from three independent experiments. (**Po0.01, Student’s t-test).
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and histone H3 phosphorylation, these changes were not
rescued in hPINK1res MEFs. p53 levels are similar up to 24 h
post-release from nocodazole block in all cells. These results
were also reﬂected in BE(2)-M17 cells transduced with the PINK1
shRNA, which showed signiﬁcantly reduced cyclin D1 expression,
and signiﬁcantly increased phospho-histone H3 levels and
Cdk1 expression compared with cells with control shRNA
(Supplementary Figure 4a). Together, these data indicate
that PINK1 promotes progression through mitosis and
cytokinesis to G1.
Multi-nucleation in PINK1-deﬁcient cells is associated with
increased mitochondrial ﬁssion
PINK1 function is inextricably linked with the maintenance of
effective mitochondrial dynamics. Mitochondrial ﬁssion/fusion
transitions are critical for cell cycle progression especially through
Figure 2. PINK1 deletion alters cell cycle proﬁle and increases multi-nucleation. (a) Senescence assay for PINK1+/+, PINK1 / and hPINK1res
MEFs, with late passage, non-immortalized p6 MEFs as positive control. Cells were ﬁxed and stained with X-gal and imaged using a light
microscope. Arrows indicate senescence-associated β-galactosidase activity occurs uniquely in p6 MEFS (blue staining). (b) Cell cycle analysis
of PINK1+/+, PINK1/ , hPINK1res and hPINK1K219A/D362A/D384A MEFs, as well as p6 non-immortalized MEFs showing representative ﬂow
cytometry analysis with histograms showing the average percentage of cells in G0/G1 (green), S (blue) and G2/M (pink) phases. Data shown
represent mean± s.e.m. of immortalized MEF cell lines derived from PINK1+/+ (n= 3) and PINK1/ (n= 3) mice (***Po0.001, **Po0.01,
Student’s t-test, when comparing G2/M and G0/G1, respectively, in PINK1 / and PINK1+/+ MEFs). hPINK1res but not hPINK1K219A/D362A/D384A
restore G2/M and G0/G1 average percentages to PINK1+/+ levels. (c) Morphological analysis of PINK1+/+, PINK1 / , hPINK1res and
hPINK1K219A/D362A/D384A MEFs. Arrows indicate multi-nucleation in representative PINK1
 / and in hPINK1K219A/D362A/D384A MEFs. Images were
taken in 10 random ﬁelds from each of three coverslips per individual sample. Histograms represent the mean percentage ± s.e.m. of multi-
nucleated cells per ﬁeld of MEF cell lines derived from PINK1+/+ (n= 3) and PINK1 / (n= 3) mice (***Po0.001, *Po0.05, Student’s t-test).
PINK1 regulates cell cycle progression
CH O’Flanagan et al
4
Oncogene (2014), 1 – 12 © 2014 Macmillan Publishers Limited
G2/M to G147, although this has never been investigated in the
context of PINK1. Mitochondrial ﬁssion during mitosis is essential
for the equal distribution of mitochondria to daughter cells,46
whereas inhibition of ﬁssion and transition to a fused state permits
progression through cytokinesis to G147. We thus hypothesized
that the regulation of mitochondrial ﬁssion/fusion by PINK1 is
important mechanistically in the transition to G1,
and that defects in this regulation are an underlying mechanism
in the failure of PINK1/ cells to complete mitosis, leading to
multi-nucleation.
Confocal microscopy revealed a small but signiﬁcant decrease
in mitochondrial interconnectivity (Figure 4a) but not elongation
Figure 3. PINK1-deﬁcient cells have impaired cell division. (a) Percentage of cells in G2/M phase of the cell cycle following release from mitotic
block with nocodazole in PINK1+/+ (circles) PINK1 / (squares), hPINK1res (triangles) and hPINK1K219A/D362A/D384A (asterisks) MEFs. Cells were
treated with 40 ng/ml nocodazole for 16 h, washed and cultured for the indicated times up to 120min in complete culture media before
being harvested for cell cycle analysis. PINK1 / MEFs and hPINK1K219A/D362A/D384A have a sustained high percentage of cells in G2/M up to
120min post-nocodazole block. Values are mean± s.e.m. of triplicate samples from three independent experiments. (b) Confocal
immunoﬂuorescence microscopy of cells following mitotic release. MEFs were harvested by mitotic shake off, seeded onto coverslips and
released from nocodazole block for 2 h before being ﬁxed and stained with 4,6-diamidino-2-phenylindole (DAPI; blue) and α-tubulin (green)
at both 0 and 2 h post-nocodazole release. Representative images of dividing cells were captured on a confocal microscope. After 2 h,
PINK1+/+ and hPINK1res MEFs have divided into daughter cells associated only by the tubulin-rich midbody at cytokinesis, PINK1
 / cells or
hPINK1K219A/D362A/D384A have not undergone cytokinesis at this time point with multiple nuclei encapsulated in one cell cytoplasm. Scale bars
5 μm. (c) Representative immunoblot analysis showing relative expression of cell cycle-associated proteins in PINK1+/+, PINK1 / and
hPINK1res MEFs, which were harvested at the indicated times up to 24 h post-release from nocodazole block. Predicted cell cycle phases
(M and G1) are indicated above the immunoblot. Expression proﬁles of phospho-H3 and cyclin D1 are signiﬁcantly altered, in PINK1 /
compared with PINK1+/+ cells and are partially rescued by hPINK1res.
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(Figure 4a), both measures of mitochondrial fusion,54 in single
nucleated PINK1/ MEFs compared with PINK1+/+ cells. Impor-
tantly, however, PINK1 / cells that exhibited multi-nucleation
were found to have a highly signiﬁcant decrease in both
mitochondrial interconnectivity and elongation, indicating major
mitochondrial fragmentation and ﬁssion in cells which fail to
divide (Figure 4a). Exogenous expression of hPINK1 rescues this
ﬁssion and hPINK1res cells demonstrated signiﬁcantly increased
levels of mitochondrial interconnectivity and elongation com-
pared with PINK1 / multi-nucleated cells (Figure 4a). Similar
results were observed when cells were ﬁxed and stained with the
nuclear stain 4,6-diamidino-2-phenylindole to identify multiple
nuclei (Figure 4b).
PINK1-deﬁciency induced G2/M defects associate with impaired
Drp1 regulation
The GTPase Drp1 is the major mediator of mitochondrial ﬁssion,
and Drp1 function has been linked to PINK1 previously,13,45 albeit
never in the context of cell cycle progression where Drp1 function
is critical.46,47,55 During mitosis, Drp1 expression, mitochondrial
recruitment and activity increase inducing mitochondrial ﬁssion.
Mitochondria are distributed to daughter cells in metaphase, and
Drp1 expression and activity decreases subsequently in anaphase
and cytokinesis, through degradation via the anaphase-promoting
complex (APC/Ccdh1),48 as mitochondria return to a more fused
morphology.46,55,56
Therefore, we investigated whether impaired regulation of
Drp1 is associated with the cell cycle defects caused by PINK1
deﬁciency. Immunoblot analysis showed Drp1 expression was
signiﬁcantly higher in PINK1/ (Figure 5a) compared with
PINK1+/+ MEFs, which was restored by overexpression of human
PINK1, but less effectively in cells expressing the kinase dead
hPINK1K219A/D362A/D384A or partial kinase dead hPINK1K219A
mutants.52 Double immunoﬂuorescence of Drp1 and MitoTracker
Green (MTG) showed Drp1 colocalized more strongly with
mitochondria in PINK1/ compared with PINK1+/+ ﬁbroblasts,
which was most evident in cells that fail to divide and exhibit
multi-nucleation (Figure 5b). Similarly, PINK1 / cells overexpres-
sing hPINK1K219A/D362A/D384A demonstrated increased Drp1/
MitoTracker Green colocalization only in their multi-nucleated
cells. Overexpression of hPINK1 rescued Drp1 cytoplasmic
localization (Figure 5b).
Phosphorylation of Drp1 at Ser585 rat sequence (Ser616 human
Drp1 variant 1) by cyclin B1/Cdk1 is essential for mitotic entry and
for increased Drp1-mediated mitochondrial ﬁssion during meta-
phase neccessary for mitochondrial distribution to daughter cells
at cytokinesis.46,47 Thereafter, APC/Ccdh1-induced degradation of
cyclin B1 coincides with reduced phospho-Drp1Ser585 levels, and
increased Drp1 degradation essential for mitotic exit and
increased mitochondrial fusion necessary for entry to G1.46,47
We found that this phosphorylation-induced regulation of Drp1
during mitosis is impaired in PINK1/ compared with PINK1+/+
cells. Upon release from nocodazole block, Drp1 and phospho-
Drp1Ser585 levels reduced slightly at 3 h in PINK1+/+ cells during G1
phase. Thereafter, both Drp1 expression and phospho-Drp1Ser585
levels increased at 6 h, as the cells initiate the next round of
mitosis and phospho-Drp1Ser585 levels migrate predominantly as a
distinctive higher molecular weight band (Figure 5c). In stark
contrast, Drp1 and phospho-Drp1Ser585 levels were signiﬁcantly
higher at time zero and all subsequent time points following
release from nocodazole block in PINK1-deﬁcient cells, where
phospho-Drp1Ser585 is only evident as the higher molecular weight
phosphorylated band at all time points (Figure 5c). This is
indicative of sustained phosphorylation at Drp1Ser585 concomitant
with prolonged residence in the mitotic pre-cytokinesis phase in
PINK1/ cells. Together, these results indicate that the multi-
nucleation and failure to exit mitosis caused by PINK1 deﬁciency is
linked to excessive mitochondrial ﬁssion, increased Drp1 expres-
sion, increased and sustained phosphorylation of Drp1Ser585, and
Figure 4. Multi-nucleation and G2/M block in PINK1 / cells is associated with increased mitochondrial ﬁssion. Representative live cell (a) and
ﬁxed (b) confocal microscopy images showing mitochondrial morphology in PINK1+/+, PINK1 / , multi-nucleated PINK1 / and hPINK1res
MEFs. Cells were transfected with pDsRed2-Mito for 12 h before being photographed. Fixed cells were permeabilized and stained with
4,6-diamidino-2-phenylindole (DAPI; blue). Scale bars 5 μm. Graphs show quantiﬁcation of mitochondrial interconnectivity and elongation
(***Po0.001, analysis of variance with Tukey's post-test; ns, nonsigniﬁcant).
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increased Drp1 mitochondrial localization. As Drp1Ser585 is
phosphorylated by cyclin B1/Cdk1, we sought to determine
whether cyclin B1/Cdk1 complexes were increased in PINK1/
compared with PINK1+/+ ﬁbroblasts. Cyclin B1 levels that co-
immunoprecipitated with Cdk1 in PINK1/ cells were marginally
higher than in PINK1+/+ cells (Supplementary Figure 4b). Together
with the higher Cdk1 levels in PINK1 / cells, this could
tentatively indicate increased activity of the complex.
Knockdown of Drp1 reduces multi-nucleation caused by PINK1
deletion
In order to further investigate the effect of mitochondrial ﬁssion
on cell cycle defects in PINK1-deﬁcient cells, we used an RNA
interference approach to suppress Drp1 expression in PINK1/
MEFs. Transfection with Drp1 siRNA resulted in a decrease of
~ 50% of Drp1 protein expression in PINK1 / MEFs (Figure 6a,
lane 3) reducing Drp1 levels to the level found in PINK1+/+ cells
(Figure 6a, ﬁnal lane). This resulted in reduced levels of
fragmented mitochondria with increased levels of tubulated,
interconnected mitochondria in PINK1/ MEFs (Figure 6b), the
characteristic morphology described previously following Drp1
knockdown.46 Morphological analysis further showed that Drp1
knockdown signiﬁcantly reduced the frequency of multi-nucleated
cells in PINK1 / MEFs (Figure 6c). Thus, inhibition of mitochon-
drial ﬁssion, via reduction of Drp1, rescues multi-nucleation
caused by PINK1 deﬁciency.
G0/G1 cell cycle exit impairment in PINK1-deﬁcient cells is also
associated with defective mitochondrial dynamics
A signiﬁcant decrease in the number of cells in G0/G1 phases was
detected in PINK1-deﬁcient MEFs (Figure 2b). To investigate this
more stringently, cells were synchronized at G0/G1 by removal of
growth factors for 24 h, with subsequent release into serum and
cell cycle analysis (Figure 7a, Supplementary Figure 5). Serum
deprivation causes cells to exit the cell cycle at G0/G1 and to
stop dividing, as occurred in PINK1+/+ ﬁbroblasts (Figure 7a).
Figure 5. (a) Representative immunoblot showing Drp1 expression in PINK1+/+, PINK1 / , hPINK1res and hPINK1K219A/D362A/D384A MEFs. Drp1
expression is increased in PINK1 / cells, which is rescued by overexpression of human PINK1 and partially rescued by overexpression of the
kinase impaired (K219A) and kinase dead (K219A/D362A/D384A) mutants. (b) Representative double immunoﬂuorescence microscopy
showing Drp1 (red) and MitoTracker green (MTG, green) colocalization with nuclei stained with 4,6-diamidino-2-phenylindole (DAPI; blue) in
PINK1+/+, PINK1 / hPINK1res and hPINK1K219A/D362A/D384A MEFs. Increased Drp1 and MTG colocalization is evident in PINK1
/ cells with
both double and single nuclei (middle panel) and more pronounced in cells with double nuclei. hPINK1K219A/D362A/D384A MEFs show increased
Drp1/MTG colocalisation, which is selective to multi-nucleated cells. Histograms show mean colocalization values± s.e.m. of Drp1 and MTG,
which is signiﬁcantly increased in PINK1 / compared to PINK1+/+ and is signiﬁcantly reduced by overexpression of human PINK1 and by
overexpression of hPINK1K219A/D362A/D384A. (*Po0.05, Student’s t-test). Scale bars 10 μm. (c) Representative western immunoblots showing
comparative Drp1, Drp1Ser585 phosphorylation and cyclin D1 protein levels in PINK1+/+ and PINK1 / MEFs at various time points up to 6 h
post-nocodazole release. Drp1 and pDrp1Ser585 are signiﬁcantly increased and have different time-dependent proﬁles in PINK1 / compared
with PINK1+/+ cells, and cyclin D1 levels are signiﬁcantly reduced at every time point in PINK1/ cells.
PINK1 regulates cell cycle progression
CH O’Flanagan et al
7
© 2014 Macmillan Publishers Limited Oncogene (2014), 1 – 12
In contrast, signiﬁcantly fewer PINK1/ cells arrested in G0/G1,
with 10% of cells remaining in G2/M. This was partially rescued in
hPINK1res, but not in hPINK1K219A MEFs, indicating PINK1 kinase
dependence, for effective cell cycle exit. Upon restoration of
serum, all cells re-entered the cell cycle, returning to their normal
proﬁle after 24 h (Supplementary Figure 5).
Reduced mitochondrial ﬁssion and increased mitochondrial
membrane potential (Δψm) have a protective role during serum
deprivation-induced cell cycle exit.50,51 Flow cytometry analysis
with the potentiometric dye tetramethylrhodamine, ethyl
ester showed that Δψm was signiﬁcantly reduced in PINK1
/
compared with PINK1+/+ ﬁbroblasts (Figure 7b), as previously
reported.14 Moreover, we found that PINK1/ MEFs did not
undergo an increase in Δψm following serum deprivation as
observed in PINK1+/+ cells (Figure 7b). Serum deprivation caused
no change to mitochondrial morphology in PINK1+/+ MEFs, with a
mix of both interconnected mitochondrial networks and punctate,
circular mitochondria observed (Figure 7c). In contrast, removal of
serum in PINK1/ MEFs caused a striking induction of punctate,
fragmented mitochondria, which was in part prevented by
overexpression of hPINK1 (Figure 7c).
Double immunoﬂuorescence microscopy of Drp1 with
pDsRed2-Mito corroborated these ﬁndings and showed increased
mitochondrially localized Drp1 upon serum deprivation in
PINK1/ MEFs compared with PINK1+/+ cells (Figure 7d). A small
percentage of mitotic cells were observed in PINK1/ MEFs
following 24-h incubation without growth factors supporting the
cell cycle analysis (Figure 7d, bottom panel, 4,6-diamidino-2-
phenylindole staining). These ﬁndings indicate that ineffective cell
cycle exit caused by the absence of PINK1 is associated with
increased Drp1-mediated mitochondrial ﬁssion and an inability to
increase Δψm following serum deprivation. Taken together, our
data indicate PINK1 regulates the cell cycle at stages critical
for division, growth and stress resistance via regulation of
mitochondrial function.
DISCUSSION
The past decade has seen substantial research into PINK1 function
since its discovery as an autosomal recessive Parkinson’s disease-
causing gene. Recently, increasing attention has implicated PINK1
in a number of processes linked to cancer,1,17,18,24–26 although
limited information is available regarding fundamental mechan-
isms for PINK1 in cancer. This study demonstrates a new role for
PINK1 as a cell cycle regulator at key points necessary for division,
growth and stress resistance in cancer, and reveals that deletion
of PINK1 inhibits several cancer-causing phenotypes including
proliferation, colony formation and migration. Results show PINK1
kinase activity is necessary for proper cell cycle progression at
G2/M speciﬁcally during cytokinesis, and during cell cycle exit at
G0/G1. Although several reports have described varied roles for
PINK1 in processes associated with cell cycle regulation, such as
mitochondrial dynamics,13,42,45 calcium ﬂux,13,57–59 phosphatidyli-
nositol 3 kinase/Akt signaling17,18 and autophagy,28 this is the
Figure 6. Inhibition of Drp1 reduces multi-nucleation caused by PINK1 deﬁciency. (a) Immunoblot analysis conﬁrming Drp1 siRNA knockdown
in PINK1/ MEFs. Cells were transfected with siRNA for 24 h before being harvested for immunoblot analysis. PINK1+/+ MEFs are included as
an internal control (ﬁnal lane). (b) Confocal microscopy showing mitochondrial morphology in pDsRed2-Mito-transfected PINK1 / MEFs,
MEFs transfected with Drp1 siRNA and negative control siRNA. Images show a mixture of fragmented and tubulated mitochondria in both
PINK1 / and PINK1/ cells transfected with negative control siRNA. Mitochondrial fragmentation is reduced in PINK1/ cells transfected
with Drp1 siRNA where cells show the characteristic morphology of fused mitochondria, indicated by the arrow. Scale bars 10 μm.
(c) Morphological analysis and quantiﬁcation of multi-nucleated cells in PINK1/ MEFs transfected with Drp1 or negative control siRNA. Cells
were grown on coverslips, ﬁxed and stained with Rapi Diff II and imaged using a light microscope. Multi-nucleated cells are evident in both
PINK1 / and PINK1 / cells transfected with negative control siRNA, but not in PINK1/ cells transfected with Drp1 siRNA. Graph
represents the mean percentage of multi-nucleated cells per ﬁeld ± s.e.m. of 10 random ﬁelds for each of three independent experiments.
Drp1 deletion in PINK1 / MEFs, but not negative control siRNA, signiﬁcantly reduced the number of cells with multiple nuclei. Values are
mean± s.e.m. (**Po0.01, analysis of variance with Tukey's post-test).
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ﬁrst study to directly implicate PINK1 in cell cycle control.
These ﬁndings provide a potential mechanism, which could
underlie several phenotypes previously described for PINK1
deﬁciency, and in the context of this study are of critical
importance for cancer cell biology.
We also show that the regulation of Drp1-mediated mitochon-
drial ﬁssion is important in the control of cell cycle progression by
PINK1 to transition from G2/M to G1 and to exit the cell cycle
following serum deprivation. It is well documented that PINK1
regulates mitochondrial ﬁssion/fusion balance via Drp113,42–45,
although this was not previously considered in the context of the
cell cycle. Previous results, as also demonstrated here, showed
that deletion of PINK1 in dividing cells causes excessive ﬁssion,
rescued by Drp1 deletion.13,45 In direct contrast, in terminally
differentiated tissues in Drosophila, Drp1 overexpression rescues
PINK1-null phenotypes.43,44,60 This conundrum could be explained
by our ﬁndings when considering the context-dependent
regulation of Drp1 at different cell cycle stages in dividing cells
and in terminally differentiated post-mitotic cells. Mitochondrial
ﬁssion/fusion and bioenergetics are emerging to be critical for
effective cell cycle progression.46,47,49,55,56 Our ﬁndings now draw
attention to the importance of further understanding the
mitochondrial functions of PINK1 in cell cycle regulation in the
context of both cancer and neurodegeneration.
Induction and completion of mitosis is essential for cancer cell
proliferation, and much of the cell cycle machinery is increased in
cancer cells.61 Indeed, cyclin D1, found here to be reduced in
PINK1-deﬁcient cells, is a major proto-oncogene and driver of cell
cycle progression.62 PINK1 inhibition was shown previously to
sensitize breast cancer cells to chemotherapeutic treatment with
paclitaxel,26 implicating PINK1 in chemoresistance. Paclitaxel
inhibits spindle disassembly, causing cell death in dividing
cells.63 Here we show that deletion of PINK1 alone can prevent
cell division, indicating a potential mechanism through which
PINK1 inhibition and treatment with paclitaxel synergistically kills
cancer cells, and lending further credence to PINK1 as a potential
target in chemoresistant tumors. Impaired mitosis in PINK1-
deﬁcient cells will constrain proliferation and likely result in death,
Figure 7. G0/G1 cell cycle exit impairment in PINK1 / cells is linked to increased mitochondrial ﬁssion and an inability to increase Δψm.
(a) Cell cycle analysis of G0/G1 synchronized PINK1+/+, PINK1 / , hPINK1res and hPINK1K219A MEFs. Cells were incubated with serum-free
media for 24 h before being harvested for cell cycle analysis. (***Po0.001, **Po0.01, Student’s t-test, when comparing G2/M and G0/G1,
respectively, in PINK1/ and PINK1+/+ MEFs). (b) Fluorescence-activated cell sorting (FACS) analysis showing reduced Δψm in PINK1 /
(overlay) MEFs compared with PINK1+/+ MEFs. Cells were stained with 50 nM tetramethylrhodamine, ethyl ester (TMRE) before being harvested
for ﬂow cytometry. PINK1 / MEFs do not undergo an increase in Δψm upon removal of serum, as observed in PINK1+/+ MEFs. At 24 h
before ﬂow cytometry, cells were incubated with or without serum. Graphs are representative of three independent experiments.
(c) Representative confocal microscopy images showing PINK1 / MEFs undergo increased levels of mitochondrial ﬁssion upon removal of
serum compared with PINK1+/+ and hPINK1res MEFs. pDsRed2-Mito-transfected PINK1+/+, PINK1 / and hPINK1res MEFs were incubated
with and without serum for 24 h. Images are representative of four independent experiments. Scale bars 5 μm. (d) Confocal
immunoﬂuorescence microscopy showing Drp1 (green) colocalization with pDsRed2-Mito-transfected (red) in PINK1+/+ and PINK1 / MEFs
incubated with and without serum for 24 h. DNA is stained with 4,6-diamidino-2-phenylindole (DAPI; blue). PINK1 / MEFs have increased
colocalization of Drp1 in mitochondria compared with PINK1+/+ both with and without serum. Bottom right panel shows a cell in anaphase
in serum starved PINK1/ MEFs substantiating failed cell cycle exit. Scale bars 10 μm.
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however, failure to properly complete cell division and aneuploidy
are feature of cancer cells.64 Thus, in certain contexts, PINK1
deletion may facilitate gain of chromosomes, increasing the
frequency of chromosomal aberrations and explain the opposing
functions described for PINK1 in cancer.24
Cell cycle aberrations have primary functions in cancer but are
also implicated in neurodegenerative disorders, where abortive
cell cycle re-entry is mechanistically linked to cell death of post-
mitotic neurons.65–68 Thus, these results have clear importance for
understanding PINK1 with respect to cell cycle regulation in
cancer, but also when considering the protective function of
PINK1 against neurodegeneration in Parkinson’s disease.
MATERIALS AND METHODS
Generation of PINK1/ mice and derived MEF cell lines
PINK1 / knockout and PINK1+/ heterozygous knockout mice were
generated by Wolfgang Wurst and Daniela Vogt-Weisenhorn (Helmholtz
Center, Munich, Germany) and immortalized MEFs were generated as
previously described.14 Immortalized MEFs from three pairs of PINK1 /
and matched PINK1+/+ mice were generated. In brief, PINK1+/ mice were
interbred to generate mutant mice and wild-type littermate controls.
Embryonic day 13 embryos were dissected, heads and red organs removed
and used for genotyping. The rest of the bodies were chopped up in cell
culture dishes containing Dulbecco’s modiﬁed Eagle's medium supplied
with 50% fetal bovine serum and 1% penicillin/streptomycin. Cultures were
expanded and serum decreased to 10% fetal bovine serum after
the attainment of consistent growth. Afterward cultures were immortalized
by transfection with simian virus 40 (SV40) large T-antigen. PINK1 /
MEFs were stably transfected with a plasmid containing human PINK1
(hPINK1 construct Origene (Rockville, MD, USA)), the partial kinase dead
hPINK1K219A and triple kinase dead hPINK1K219A/D362A/D384A mutants using
site-directed mutagenesis (Stratagene, Santa Clara, CA, USA). hPINK1
expression was conﬁrmed using RNA extraction and analysis. As indicated,
experiments were performed using MEF lines from three pairs of PINK1+/+
and PINK1 / mice.
Cell culture and cell synchronization
MEFs, MCF-7 and HeLa cells were cultured in dulbecco’s modiﬁed eagle's
medium supplemented with 10% fetal bovine serum and 2mM
L-glutamine in a humidiﬁed atmosphere containing 5% CO2 at 37 °C. BE
(2)-M17 cells transduced with PINK1 shRNA or with control shRNA were
kindly provided by Mark Cookson and Alexandra Beilina NIA, Bethesda,
MD, USA and were transduced and cultured as previously described.13
G2/M synchronization was achieved by treatment with 40 ng/ml
nocodazole in complete media for 16 h. Cells were synchronized at
G0/G1 phase by incubation with serum-free dulbecco’s modiﬁed eagle's
medium for 24 h.
Plasmids, siRNA and shRNA transfection
MEFs were transfected with pDsMitoRed2-Mito (Clontech, Palo Alto, CA,
USA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions and incubated with DNA/Lipofectamine
transfection mix for at least 12 h before being imaged on a Zeiss LSM 510
META Confocal microscope (Jena, Germany) or being ﬁxed for immuno-
ﬂuorescence. For siRNA knockdown, MCF-7 cells or PINK1 / MEFs were
transfected for 24–48 h with 100 nM negative control siRNA (Ambion,
Austin, TX, USA), PINK1-targeting siRNA (Qiagen, Germantown, MD, USA) or
Drp1-targeting siRNA (Sigma, St Louis, MO, USA) using HiPerfect (Qiagen)
according to the manufacturer’s instructions. Stable PINK1 knockdown was
achieved in HeLa cells using a 29mer shRNA construct against human
PINK1 cloned into a retroviral untagged vector (Origene). The shRNA
sequence was 5′-CCAGAACCTGGAGGTGACAAAGAGCACCG-3′. Cells were
transfected with Lipofectamine 2000 and selected with 5 μg/ml puromycin.
Proliferation and colony formation assays
Cells were seeded at 4 × 104 cells per well in a 24-well plate. To monitor cell
growth at intervals, attached cells were removed from quadruplicate wells
using trypsin-ethylenediaminetetra acetic acid and viable cells counted by
Trypan blue exclusion. Anchorage-independent cell growth was deter-
mined by assaying colony formation in soft agarose as described
previously.69 In all, 1 × 103 cells were resuspended in 0.33% low-melting
point agarose (Sigma) in dulbecco’s modiﬁed eagle's medium/10% fetal
bovine serum and plated in triplicate onto 35-mm dishes containing a 2-ml
base agarose layer (0.6%). After 14 days, colonies were stained with 0.01%
crystal violet in 20% ethanol and counted.
Migration and invasion assays
Cells were plated in triplicate in six-well plates. Conﬂuent monolayers were
scratched using a sterile tip (time 0 h) and cells were allowed to migrate
into the wound for 8 h. Wound closure was determined comparing the
same ﬁeld at 0 and 8 h using T-Scratch software.70 For invasion assays,
1 × 105 cells were allowed to migrate into a 5 μM pore Transwell, pre-coated
with 7 mg/ml Matrigel (BD Biosciences, Heidelberg, Germany). After 24 h,
cells were ﬁxed with 100% methanol, stained with 0.1% crystal violet and
counted using a light microscope.
Cell cycle analysis and ﬂow cytometry
For cell cycle analysis, cells were resuspended in ice-cold phosphate-
buffered saline. Before ﬂow cytometry, NP-40 and propidium iodide
(Sigma) were added at a ﬁnal concentration of 0.1% and 50 μg/ml,
respectively. DNA content was measured in the FL2 channel using
CellQuest software (Becton Dickinson, Oxford, UK). Δψm was measured by
incubation with 50 nM tetramethylrhodamine, ethyl ester (Molecular
Probes, Eugene, OR, USA) before being harvested for ﬂow cytometry, with
Δψm measured in the FL2 channel.
Confocal microscopy and morphological analysis
Fluorescence images were acquired Zeiss LSM 510 META confocal
microscope ﬁtted with a 63 × /1.4 plan apochromat lens (Jena, Germany).
For details of confocal microscopy and morphological analysis, see
Supplementary Materials and methods.
Western blot analysis
Proteins were extracted for sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and western immunoblot analysis was performed as
described in Supplementary Materials and methods.
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